AGENDA

I. Call to Order
II. Welcome & Introductions
III. Administrative Matters
IV. Approval of February 13, 2018 Meeting Minutes
V. PDL Compliance/Generic Percent Report Updates
VI. Drug Class Announcements
VII. Public Comment
VIII. Therapeutic Class Reviews-
   a. Antivirals (oral)- adding Cytomegalovirus Agents
   b. Opiate Dependence Treatments- adding Probuphine, Sublocade, Vivitrol
IX. New Drug/New Generic Reviews
    a. Antibiotics, GI- Solosec (secnidazole)
    b. Antiretrovirals- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
    c. Hypoglycemics
       1. Incretin Mimetics/Enhancers- Ozempic (semaglutide)
       2. Insulins and Related Agents- Admelog (insulin lispro)
       3. Sodium Glucose Cotransporter 2 Inhibitor- Steglatro (ertugliflozin)
       4. Sodium Glucose Cotransporter 2 Inhibitor Combinations
          a. Segluromet (ertugliflozin/metformin)
          b. Steglujan (ertugliflozin/sitagliptin)
    d. Neuropathic Pain- Lyrica CR (pregabalin)
X. Other Business
   a. Distribution of Electronic P&T Materials
XI. Division of Medicaid Update
XII. Next Meeting Dates
    a. Tuesday, August 14, 2018
    b. Tuesday, October 23, 2018
XIII. Adjournment